REFRACTORY MALIGNANT GLIOMA

This study is testing an oral medication called tipifarnib in children and young adults (ages 1-21) whose advanced solid tumors, lymphoma, or histiocytic disorders have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control t…

This study is testing how well a drug called selpercatinib works for children and young adults with advanced or hard-to-treat cancers that have a specific genetic change in the RET gene. The drug is designed to block the growth of cancer cells with this change. Participants take …

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This early-phase trial is testing a new type of personalized immunotherapy for patients with malignant brain tumors (gliomas) that have returned or stopped responding to standard treatments. Doctors collect a patient's own immune cells (T-cells), genetically modify them in a lab …

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …